A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases
NCT06512883
·
clinicaltrials.gov ↗
PHASE3
Phase
RECRUITING
Status
14
Enrollment
INDUSTRY
Sponsor class
Conditions
Eosinophilic Granulomatosis With Polyangiitis (EGPA)
Hypereosinophilia Syndrome (HES)
Interventions
DRUG:
Benralizumab
Sponsor
AstraZeneca